BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story

Key Points

• BWX Technologies is selling its medical business to Nordic Capital for up to $800 million, sharpening its focus on nuclear defense and commercial power.
• BWX Technologies reported strong Q2 results, raised 2026 guidance and ended the quarter with a backlog of about $8.39 billion.
• BWX Technologies could benefit from rising nuclear demand tied to AI data centers, but valuation, regulation and execution risks remain important.

The artificial intelligence (AI) revolution is running into a severe physical roadblock: the electrical grid. Data centers consume extraordinary amounts of electricity, and tech giants are scrambling to secure reliable, carbon-free baseload power. Wind and solar lack the consistency required to run generative AI models around the clock, leaving nuclear energy as the most viable long-term solution. This macroeconomic shift creates a generational tailwind for businesses that supply the physical hardware enabling advanced nuclear power.

BWX Technologies NYSE: BWXT recently made a decisive move to dominate this space. By reaching a definitive agreement to sell its medical isotopes business to Nordic Capital for up to $800 million, BWX Technologies is stripping away non-core assets to become a hyper-focused, pure-play nuclear energy and defense contractor. The strategic pivot strengthens the balance sheet by providing immediate liquidity, capital needed to scale small modular reactor production and expand naval propulsion output.

Weaponizing Liquidity: An $800M Atomic Pivot

BWX Technologies originally acquired its medical isotopes division in 2018, steadily growing the unit and tripling its revenue over the last several years. While highly accretive, the medical segment ultimately operated tangentially to the primary competency of building nuclear reactors and propulsion components.

Offloading this division to Nordic Capital is a strategic masterstroke in capital allocation. It generates a cash injection of up to $800 million that can be deployed directly into national security operations and commercial nuclear power expansion without tapping high-cost debt markets.

The deal's structure also provides a safety net. Management retained a minority ownership stake in the divested medical entity, ensuring shareholders still capture some upside in the rapidly growing radiopharmaceutical market. The primary operational focus is now firmly on the nuclear renaissance.

Critical Mass: A Backlog Built for the Next Decade

Looking at the second-quarter earnings report from August 2026, the pivot toward commercial nuclear applications is already executing at scale. Commercial operations revenue surged 72% year-over-year to $302.5 million. This breakout growth validates the strategy to concentrate resources on heavy nuclear infrastructure. Total revenue for BWX Technologies reached about $901 million, an 18% increase from the same quarter last year.

Total backlog swelled to around $8.39 billion, up from $6.01 billion in the second quarter of 2025. A backlog of this magnitude insulates the balance sheet against near-term economic volatility. It provides long-term cash flow predictability, allowing management to confidently forecast revenue and allocate resources years into the future.

To further support this commercial expansion, BWX Technologies closed its acquisition of Precision Components Group, announced on July 6, 2026. This acquisition instantly scales domestic manufacturing capacity, establishing a dedicated U.S. footprint specifically designed for commercial nuclear component production.

Controlling the manufacturing supply chain is a critical advantage as global demand for nuclear hardware accelerates. Precision Components Group brings specialized welding and machining capabilities that directly complement existing naval nuclear operations, creating operational savings that should begin reflecting in operating margins over the next several quarters.

How SMRs Will Fuel the Future

The broader market is just beginning to understand the severe energy demands of the artificial intelligence data center build-out. Regional power grids are already feeling the strain, forcing utility operators to rethink their long-term capacity models. Small modular reactors offer a scalable, factory-built solution that can be deployed faster and cheaper than traditional large-scale nuclear plants.

Because of its deep history supplying nuclear propulsion systems to the U.S. Navy, BWX Technologies already possesses the specialized engineering talent, regulatory clearances, and heavy manufacturing facilities required to dominate the small modular reactor supply chain.

The capital injection from the medical divestiture will fund the necessary capacity expansion to meet this impending wave of commercial demand. Institutional infrastructure funds and clean energy portfolios are increasingly recognizing nuclear power as a necessary component of the energy transition, creating a structural bid for pure-play nuclear equities. As data center operators begin signing long-term purchase agreements for nuclear baseload power, businesses that produce the core components of nuclear reactors are positioned to capture a large share of the value chain.

Half-Life of a Pullback: Why Fundamentals Win Out

Despite strong fundamentals and raised forward guidance, BWX Technologies has experienced a roughly 9% pullback over the past 30 days. Currently trading near $172, this margin compression appears strictly tied to broader market rotations rather than any underlying fundamental weakness. Insiders have executed some net selling, but given the equity's 225% appreciation over the trailing five years, this distribution aligns with standard executive profit-taking rather than internal distress.

The underlying financials tell a story of balance sheet health. Post-earnings, management raised the 2026 earnings before interest, taxes, depreciation, and amortization guidance to a range of $662 million to $672 million. Non-GAAP earnings per share forecasts were bumped to $4.70 to $4.80. BWX Technologies also raised its free cash flow outlook to $345 million to $360 million.

Sustaining capital returns while orchestrating a structural divestiture is a clear signal of confidence. Management maintained the regular quarterly dividend of 27 cents per share, payable on Sept. 4, 2026. Wall Street is taking notice of these robust cash flows. BTIG reiterated a Buy rating immediately following the earnings release, maintaining a $235 price target. This target implies an upside of roughly 35% from current levels.

The Final Countdown: Positioning for the Nuclear Age

The transition into a pure-play nuclear defense and commercial power supplier removes a layer of complexity from the business model. Investors no longer have to model out the intricacies of the medical radioisotope market when valuing BWX Technologies. The investment thesis is now cleanly tied to the global expansion of nuclear energy and a growing defense budget.

While the trailing price-to-earnings ratio sits around 47, the forward multiple contracts to about 38, reflecting the earnings growth expected in the back half of the decade. Investors must recognize that small modular reactor deployment timelines remain relatively long, and regulatory hurdles could delay some commercial projects. Any execution missteps in integrating Precision Components Group or expanding existing facilities could temporarily weigh on margins.

Investors looking to capitalize on the widening energy deficit created by artificial intelligence data centers might want to add BWX Technologies to their watchlist as commercial nuclear demand accelerates. Cautious investors may prefer to wait for BWX Technologies to establish a firm base around the $170 level before taking a position, keeping a close eye on the upcoming close of the Nordic Capital transaction.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source